Trastuzumab Emtansine [TRA1]

The treatment of HER2-positive locally advanced/ unresectable or metastatic (Stage IV) breast cancer where all the following criteria are met:

  1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
  2. Progression of her-2 positive locally advanced or metastatic breast cancer
  3. Progression during or after the most recent treatment for advanced stage disease or within 6 months of completing treatment for early stage disease
  4. Previous treatment with a taxane
  5. Previous treatment with trastuzumab
  6. Perfomance statau of 0, 1 or 2
  7. Left ventricular ejection fraction of 50% or more
  8. NOTE: not to be used beyond first disease progression outside the CNS. Do not discontinue if disease progression is within the CNS alone
  9. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).
  10. will otherwise be used as set out in its Summary of Product Characteristics (SPC). Note: To minimise the risk of errors due to the similarity of the product name Trastuzumab Emtansine (Kadcyla) with that of Trastuzumab the recommendations in the Risk Minimisation Plan educational material from the manufacturer should be followed when prescribing, dispensing and administering the product

[NHS funded]{.badge .rounded-pill .bg-success} From: 17 October 2017

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA458 TA371) (19 July 2017)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.